Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Rating Increased to Strong-Buy at The Goldman Sachs Group

Posted by Teresa Graham on Jun 16th, 2026

The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Free Report) from a hold rating to a strong-buy rating in a research note published on Monday morning,Zacks.com reports.

Separately, Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

Read Our Latest Research Report on SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

SGIOY stock opened at $8.85 on Monday. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.65 and a 12-month high of $12.00. The company has a market cap of $15.06 billion, a price-to-earnings ratio of 11.06, a PEG ratio of 3.32 and a beta of 0.08. The firm has a 50 day moving average of $9.70 and a 200-day moving average of $9.89. The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The company had revenue of $881.71 million for the quarter, compared to analyst estimates of $895.52 million. As a group, equities analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.